Kanagawa Prefecture renews MoU on regenerative medicine and cell therapy with Cell and Gene Therapy Catapult

Kanagawa Prefecture announces their renewed Memorandum of Understanding (MoU) in regenerative medicine and cell therapy with Cell and Gene Therapy Catapult (CGT Catapult), which was last signed in November 2015. CGT Catapult is a UK organisation supporting the commercialisation of cell and gene therapy.

This MoU builds upon the previous agreement which was announced on 30 November 2015, and seeks to further the cooperation between the two countries in the practical application and commercialisation of regenerative medicine and cell therapy, providing partnerships which enable both Japanese and British firms to internationalise the development of these advanced therapies.

Outline of MOU

1.1 Purpose

  • To deepen the mutual understanding, friendship, and cooperation between the UK and Japan in promoting scientific and technological developments. To develop both regions by facilitating the practical realisation and industrialisation of regenerative medicine and cell therapy.

1.2 Main collaborative areas

  • Supporting collaboration of joint research to work towards the practical industrialisation in the field of regenerative medicine and cell therapy
  • Maintaining cooperation between the expertise at CGT Catapult Stevenage in the UK and the Life Innovation Centre in Japan’s Kanagawa Prefecture
     

About CGT Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 330 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or visit http://www.gov.uk/innovate-uk.

Contact

神奈川県政策局ヘルスケア・ニューフロンティア推進本部室

Kanagawa Prefecture Policy Bureau Healthcare New Frontier Promotion Headquarters Office

Director of International Strategy, 太田 Ota - Tel 045-210-2720

Global Strategy Group, 松本 Matsumoto - Tel 045-210-2725

Discover who we are